arrow_back Back to App

Enhanced Transparency for Pharmacy Benefit Managers: New Rules for Drug Pricing

New regulations aim to increase transparency in the operations of Pharmacy Benefit Managers (PBMs) that negotiate drug prices. This will give citizens and insurance plans better insight into how much money PBMs receive from drug manufacturers and how much of that is passed back to the plans. These changes could potentially impact drug costs and healthcare benefits, making them more understandable.
Key points
Pharmacy Benefit Managers (PBMs) will be required to disclose more information about their revenues and fees related to prescription drugs.
PBMs must report how much money they receive from pharmaceutical manufacturers and what percentage of these funds is passed through to health plans.
The government will publish annual reports summarizing this data, increasing public oversight of the drug market.
The changes will take effect from January 1, 2027, allowing time for adaptation to the new requirements.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_7717
Sponsor: Rep. Gallego, Ruben [D-AZ-3]
Process start date: 2024-03-19
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

To amend title XI of the Social Security Act to enhance pharmacy benefit manager transparency requirements.

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_7717.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2024-03-19.

What are the main provisions?

Key points include:

  • Pharmacy Benefit Managers (PBMs) will be required to disclose more information about their revenues and fees related to prescription drugs.
  • PBMs must report how much money they receive from pharmaceutical manufacturers and what percentage of these funds is passed through to health plans.
  • The government will publish annual reports summarizing this data, increasing public oversight of the drug market.
  • The changes will take effect from January 1, 2027, allowing time for adaptation to the new requirements.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Gallego, Ruben [D-AZ-3].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health